Description
Biotinylated Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Complex Protein (Monomer, MALS verified) | HLW-H82E5-25ug| Gentaur Distribution US, UK & Europe
Wilms tumor gene 1 (WT1) ，is an attractive target antigen for leukemia and solid cancer. WT1-specific adoptive immunotherapy has developed for tumor treatment in recent years. WT1 has been proved wildly expressed in breast, colon and ovarian cancer. It participates in cell growth, differentiation and apoptosis regulation. The WT1127-134 (RMFPNAPYL) was shown to be recognized by HLA-A*0201 tumor-infiltrating lymphocytes from melanoma patients, and therefore it is widely been studied in TCR-T studies. The Human HLA-A*0201 WT-1 (RMFPNAPYL) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and RMFPNAPYL peptide of the WT-1.
Source: Biotinylated Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Complex Protein (HLW-H82E5) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Thr 305 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & RMFPNAPYL peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769 (B2M) & RMFPNAPYL).
Format: Powder.
Tag: C-10×His & C-Avi.
Expression System: HEK293.
Expression Region: Gly 25 - Thr 305 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & RMFPNAPYL peptide.
Conjugate: Biotin-labeled.
Molecular Weight: 36.0 kDa and 13.9 kDa.
Characteristics: Biotinylated Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Complex Protein is produced by co-expression of HLA and B2M loaded with WT-1 peptide. This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™). The protein has a calculated MW of 36.0 kDa and 13.9 kDa. The protein migrates as 42-45 kDa and 14 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Purity: 95%.
Buffer: PBS, pH7.4.
Storage Conditions: -20℃.
Shipping Conditions: RT
